

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8055537

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
CONVEYING PARTY DATA	
Name	Execution Date
HDL THERAPEUTICS	07/01/2014
RECEIVING PARTY DATA	
Name:	HDL Therapeutics, Inc.
Street Address:	601 21st Street
Internal Address:	Suite 300
City:	Vero Beach
State/Country:	FLORIDA
Postal Code:	32960
PROPERTY NUMBERS Total: 6	
Property Type	Number
Patent Number:	7375191
Patent Number:	7361739
Patent Number:	7393826
Patent Number:	8030281
Patent Number:	8048015
Patent Number:	8268787
CORRESPONDENCE DATA	
Fax Number:	(714)464-5413
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	949-795-2386
Email:	michael@novelip.com
Correspondent Name:	SONA DALAL
Address Line 1:	191 WEST SECOND STREET
Address Line 4:	SANTA ANA, CALIFORNIA 92701
ATTORNEY DOCKET NUMBER:	HDL_6PATENTS_HDLT_HDLTINC
NAME OF SUBMITTER:	SONA DALAL
SIGNATURE:	/SONA DALAL/
DATE SIGNED:	07/13/2023

Total Attachments: 7

source=HDL_TherapeuticsInc_Certificate of Incorporation#page1.tif

source=HDL_TherapeuticsInc_Certificate of Incorporation#page2.tif

source=HDL_TherapeuticsInc_Certificate of Incorporation#page3.tif

source=HDL_TherapeuticsInc_Certificate of Incorporation#page4.tif

source=HDL_TherapeuticsInc_Certificate of Incorporation#page5.tif

source=HDL_TherapeuticsInc_Certificate of Incorporation#page6.tif

source=HDL_TherapeuticsInc_Certificate of Incorporation#page7.tif

Delaware

PAGE 1

The First State

I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF "HDL THERAPEUTICS, INC.", FILED IN THIS OFFICE ON THE FIRST DAY OF JULY, A.D. 2014, AT 6:09 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.

4749292 8100

140909808

You may verify this certificate online
at corp.delaware.gov/authver.shtml




Jeffrey W. Bullock, Secretary of State
AUTHENTICATION: 1510197

DATE: 07-03-14

PATENT
REEL: 064271 FRAME: 0916

SECOND AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
HDL THERAPEUTICS, INC.

(Pursuant to Sections 242 and 245 of the
General Corporation Law of the State of Delaware)

HDL Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the "**General Corporation Law**"),

DOES HEREBY CERTIFY:

1. That the name of this corporation is HDL Therapeutics, Inc., and that this corporation was formed on January 29, 2013. The company was originally formed on November 3, 2009 under the name HDL Therapeutics LLC and thereafter filed a conversion on January 29, 2013 and was incorporated pursuant to the General Corporation Law under the name HDL Therapeutics, Inc.

2. That the Board of Directors duly adopted resolutions proposing to amend and restate the Certificate of Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows:

RESOLVED, that the Certificate of Incorporation of this corporation be amended and restated in its entirety to read as follows:

FIRST: The name of this corporation is HDL Therapeutics, Inc. (the "**Corporation**").

SECOND: The address of the registered office of the Corporation in the State of Delaware is 2711 Centerville Road, Suite 400, Wilmington, County of New Castle, 19808. The name of its registered agent at such address is Corporation Service Company.

THIRD: The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law.

FOURTH: The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 20,000,000 shares of Common Stock, \$.0001 par value per share ("**Common Stock**"), and (ii) 4,000,000 shares of Preferred Stock, \$.0001 par value per share ("**Preferred Stock**").

FIFTH: The following is a statement of the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of the Common Stock.

ELEVENTH: To the fullest extent permitted by law, a director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the General Corporation Law or any other law of the State of Delaware is amended after approval by the stockholders of this Article Eleventh to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law as so amended.

Any repeal or modification of the foregoing provisions of this Article Eleventh by the stockholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to any acts or omissions of such director occurring prior to, such repeal or modification.

TWELFTH: To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which General Corporation Law permits the Corporation to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section 145 of the General Corporation Law.

Any amendment, repeal or modification of the foregoing provisions of this Article Tenth shall not adversely affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or modification.

* * *

3. That the foregoing amendment and restatement was approved by the holders of the requisite number of shares of this corporation in accordance with Section 228 of the General Corporation Law.

4. That this Second Amended and Restated Certificate of Incorporation, which restates and integrates and further amends the provisions of this Corporation's Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law.

IN WITNESS WHEREOF, this Amended and Restated Certificate of Incorporation has been executed by a duly authorized officer of this corporation on this 1st day of July, 2014.

By: 

Name: Michael Martin

Title: Chief Executive Officer

FIFTH AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
HDL THERAPEUTICS, INC.

(Pursuant to Sections 242 and 245 of the
General Corporation Law of the State of Delaware)

HDL Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the "**General Corporation Law**"),

DOES HEREBY CERTIFY:

1. That the name of this corporation is HDL Therapeutics, Inc., and that this corporation was formed on January 29, 2013. The company was originally formed on November 3, 2009 under the name HDL Therapeutics LLC and thereafter filed a conversion on January 29, 2013 and was incorporated pursuant to the General Corporation Law under the name HDL Therapeutics, Inc.

2. That the Board of Directors duly adopted resolutions proposing to amend and restate the Certificate of Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of the relevant stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows:

RESOLVED, that the Certificate of Incorporation of this corporation be amended and restated in its entirety to read as follows:

FIRST: The name of this corporation is HDL Therapeutics, Inc. (the "**Corporation**").

SECOND: The address of the registered office of the Corporation in the State of Delaware is 251 Little Falls Drive, Wilmington, County of New Castle, 19808. The name of its registered agent at such address is Corporation Service Company.

THIRD: The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law.

FOURTH: The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 20,000,000 shares of Common Stock, \$0.0001 par value per share ("**Common Stock**"), and (ii) 6,382,662 shares of Preferred Stock, \$0.0001 par value per share ("**Preferred Stock**").

FIFTH: The following is a statement of the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of the Common Stock.

the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation.

EIGHTH: Subject to any additional vote required by this Certificate of Incorporation, the number of directors of the Corporation shall be determined in the manner set forth in the Bylaws of the Corporation.

NINTH: Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.

TENTH: Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws of the Corporation may provide. The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors or in the Bylaws of the Corporation.

ELEVENTH: To the fullest extent permitted by law, a director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the General Corporation Law or any other law of the State of Delaware is amended after approval by the stockholders of this Article Eleventh to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law as so amended.

Any repeal or modification of the foregoing provisions of this Article Eleventh by the stockholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to any acts or omissions of such director occurring prior to, such repeal or modification.

TWELFTH: To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which General Corporation Law permits the Corporation to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section 145 of the General Corporation Law.

Any amendment, repeal or modification of the foregoing provisions of this Article Twelfth shall not adversely affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or modification.


* * *

3. That the foregoing amendment and restatement was approved by the holders of the requisite number of shares of this Corporation in accordance with Section 228 of the General Corporation Law.

4. That this Fifth Amended and Restated Certificate of Incorporation, which restates and integrates and further amends the provisions of this Corporation's Certificate of

Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law.

IN WITNESS WHEREOF, this Fifth Amended and Restated Certificate of Incorporation has been executed by a duly authorized officer of this corporation on this 19th day of September, 2019.

By: 
Name: Michael Matin
Title: Chief Executive Officer

*[Signature Page to Fifth Amended and Restated Certificate of Incorporation of
HDL Therapeutics, Inc.]*